About me
Jordan Zwick is our Chief Business Officer. Mr. Zwick is an experienced leader in corporate strategy and business development in the biopharmaceutical sector. Mr. Zwick served as strategic advisor to Prometheus Biosciences prior to its sale to Merck in June 2023. Previously, Mr. Zwick served as SVP, Corporate Business Development and Investor Relations at Amarin Corp (AMRN), closing multiple transactions for global partnering of the lead asset. Jordan served as SVP, Chief Strategy Officer at InflaRx N.V. (IFRX), where he was responsible for leading corporate strategy, business & corporate development, investor relations and was instrumental in the public financings of the Company. Mr. Zwick has vast industry operational experience at companies such as Medtronic, Salix Pharmaceuticals and Bausch Health. As part of the team that sold Salix to Valeant Pharmaceuticals (now Bausch Health Companies) for $14.5 billion in 2015, Mr. Zwick eventually became head of strategy at the Salix business unit, responsible for leading all business development transactions, alliance management, strategic planning and portfolio management, playing a key role in the turnaround story of Bausch Health. He holds B.A., M.S. degrees from Florida Atlantic University and a M.B.A. from the University of San Francisco.